Scholarlink

Background <p>Thrombotic molecular markers include the thrombin-antithrombin complex (TAT), plasmin inhibitor-plasmin complex (PIC), thrombomodulin (TM), and tissue plasminogen activator-plasminogen activator inhibitor-1 complex (t-PAIC). These molecular markers facilitate the early assessment of coagulation and fibrinolysis system functions, as well as vascular endothelial injury; however, their clinical application following intravenous thrombolysis for acute ischemic stroke (AIS) remains unclear. Therefore, our study aims to evaluate the dynamic levels of these novel thrombosis-related molecular markers within 24&#xa0;h after intravenous thrombolysis in patients with AIS and analyze their relationship with patients outcome.</p> Methods <p>We conducted a retrospective cohort study based on the data of 77 patients with AIS who underwent alteplase intravenous thrombolysis between November 2022 and February 2024. Thrombotic molecular markers were evaluated at four time points: prior to thrombolysis, 1&#xa0;h after thrombolysis, 6&#xa0;h after thrombolysis, and 24&#xa0;h after thrombolysis. Based on the modified Rankin scale (mRS) score at day 90 post-discharge, patients were categorized into the excellent outcome group (mRS ≤ 1) and the non-excellent outcome group (mRS &gt; 1). Stepwise multivariate logistic regression was employed to analyze the association between 90-day functional outcomes and the measured variables. The area under the receiver operating characteristic curve (AUC) was utilized to assess the predictive ability of novel thrombotic markers.</p> Results <p>Our study demonstrated that, compared to the non-excellent outcome group, the excellent outcome group exhibited significant lower serum TAT levels both prior to thrombolysis and at 6&#xa0;h post-thrombolysis (all <i>p</i> &lt; 0.05), and serum TM and t-PAIC levels were also significantly elevated in the excellent outcome group at 1&#xa0;h, 6&#xa0;h, and 24&#xa0;h following thrombolysis (all <i>p</i> &lt; 0.05). Stepwise logistic regression analysis indicated that increased serum TM and t-PAIC levels at 24&#xa0;h post-thrombolysis were protective factors for a excellent 90-day outcome. The AUC values of TM, t-PAIC, and TM combined with t-PAIC for predicting 90-day functional outcomes were 0.918 (sensitivity 80.0%; specificity 85.7%), 0.658 (sensitivity 91.4%; specificity: 45.2%), and 0.984 (sensitivity: 97.1%; specificity 97.6%), respectively.</p> Conclusion <p>Thrombotic molecular markers might serve as indicators for the early monitoring of dysfunction in the coagulation-fibrinolysis system and endothelial injury following intravenous thrombolysis for AIS. TM and t-PAIC exhibit predictive value regarding the outcome of intravenous thrombolysis in AIS, providing insights for future research on the protective role of TM in AIS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dynamic alterations of thrombotic molecular markers in acute ischemic stroke patients after intravenous thrombolysis: a prospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月4日

查看全文
  • Wei Sun,
  • Shuhua Xie,
  • Fugan Liu,
  • Yuqing Xie,
  • Yunhui Zhu,
  • Pengcheng Wu,
  • Jiajia Zhu,
  • Xianghong Liu

摘要

Background

Thrombotic molecular markers include the thrombin-antithrombin complex (TAT), plasmin inhibitor-plasmin complex (PIC), thrombomodulin (TM), and tissue plasminogen activator-plasminogen activator inhibitor-1 complex (t-PAIC). These molecular markers facilitate the early assessment of coagulation and fibrinolysis system functions, as well as vascular endothelial injury; however, their clinical application following intravenous thrombolysis for acute ischemic stroke (AIS) remains unclear. Therefore, our study aims to evaluate the dynamic levels of these novel thrombosis-related molecular markers within 24 h after intravenous thrombolysis in patients with AIS and analyze their relationship with patients outcome.

Methods

We conducted a retrospective cohort study based on the data of 77 patients with AIS who underwent alteplase intravenous thrombolysis between November 2022 and February 2024. Thrombotic molecular markers were evaluated at four time points: prior to thrombolysis, 1 h after thrombolysis, 6 h after thrombolysis, and 24 h after thrombolysis. Based on the modified Rankin scale (mRS) score at day 90 post-discharge, patients were categorized into the excellent outcome group (mRS ≤ 1) and the non-excellent outcome group (mRS > 1). Stepwise multivariate logistic regression was employed to analyze the association between 90-day functional outcomes and the measured variables. The area under the receiver operating characteristic curve (AUC) was utilized to assess the predictive ability of novel thrombotic markers.

Results

Our study demonstrated that, compared to the non-excellent outcome group, the excellent outcome group exhibited significant lower serum TAT levels both prior to thrombolysis and at 6 h post-thrombolysis (all p < 0.05), and serum TM and t-PAIC levels were also significantly elevated in the excellent outcome group at 1 h, 6 h, and 24 h following thrombolysis (all p < 0.05). Stepwise logistic regression analysis indicated that increased serum TM and t-PAIC levels at 24 h post-thrombolysis were protective factors for a excellent 90-day outcome. The AUC values of TM, t-PAIC, and TM combined with t-PAIC for predicting 90-day functional outcomes were 0.918 (sensitivity 80.0%; specificity 85.7%), 0.658 (sensitivity 91.4%; specificity: 45.2%), and 0.984 (sensitivity: 97.1%; specificity 97.6%), respectively.

Conclusion

Thrombotic molecular markers might serve as indicators for the early monitoring of dysfunction in the coagulation-fibrinolysis system and endothelial injury following intravenous thrombolysis for AIS. TM and t-PAIC exhibit predictive value regarding the outcome of intravenous thrombolysis in AIS, providing insights for future research on the protective role of TM in AIS.